TABLE 2.

Median responses of 18 quality of life (QoL) questions

		QoL questions
		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
	n	EuroQoL‐5D‐5L				HADS		EORTC QLQ C30							BIPQ
Entire group
Age (years)
≤65	60	73	1	1	2	6	5	5	5	2	2	2	2	2	4	8	6.5	3	6
>65	95	79.5	1	1	2	4	4	5	6	2	2	2	2	1	4	8	6	3	5
p‐Value						0.01
Gender
Male	87	80	1	1	2	4	4	5	5	2	2	2	2	2	5	8	6	3	6
Female	68	73.5	1	1	2	5	5	5	5	2	2	2	2	2	4	8	6	3	5
p‐Value						0.01
WM‐associated disorder
Yes	8	71	1	1	2	6.5	3.5	5	6	2	2	2	2	2	6	8	7.5	5	7
No	147	75	1	1	2	4.5	4	5	5	2	2	2	2	2	4	8	6	3	5
Clinical details
Years since diagnosis
≤5 years	23	73	1	2	2	6	5	5	6	2	2	2	2	2	4	8	7	3	6
>5 years	42	74	1	1	2	4	3	5	5	2	2	2	2	2	5	8	6	4	6
Present treatment status
On treatment	17	76	1	1	1	5.5	2	6	6	2	2	1	2	1	6	8	6	4	5
Off treatment	35	73	1	2	2	4	5	5	5	2	2	2	2	2	4	8	6	4	7
p‐Value				0.02			0.01
Current treatment
BTKi	13	77.5	1	1	1	4.5	1	6	6	2	2	1	2	1	6	8	6	3	3
Chemotherapy	4	53.5	1	2	1	6	5	5.5	5	2.5	2	1.5	1	2	2	9	9	6	6.5
p‐Value							0.03

Abbreviations: BTKi, Bruton's tyrosine kinase inhibitor; WM, Waldenström macroglobulinaemia.